Screening for participants with eye diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study allows doctors at the National Eye Institute (NEI) to examine individuals with known or unknown eye diseases to assess their eligibility for other NEI research studies. Participants of all ages may undergo a variety of tests, including medical history reviews, physical examinations, eye exams, and genetic testing. The study aims to identify suitable candidates for ongoing clinical research and to collect biospecimens for future laboratory research on eye diseases. No treatment is provided in this study, but participants may receive recommendations for their primary care.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

Participants will be able to enroll if they:

* Have a diagnosed ocular disease/disorder; OR
* Potentially have an unusual, interesting, or unknown ocular condition that requires the establishment of a diagnosis; OR
* Potentially participate as a disease-free control participant in an NEI clinical research study; OR
* Are an unaffected first-degree relative of a participant with either a diagnosed or undiagnosed ocular disorder; AND
* Have the ability to understand and sign an informed consent OR if they are minor children have a legal parent/guardian with the ability to do the same.
* Adults with impaired capacity to consent must have a Legally Authorized Representative (LAR) who is able to provide informed consent.

EXCLUSION CRITERIA:

Participants will be unable to enroll if they:

* Are unwilling or unable to cooperate with the study procedures.
* Female participants of childbearing potential who are pregnant are not eligible for enrollment.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Awilda V Holland, R.N. — National Eye Institute (NEI)
• Study coordinator: Awilda V Holland, R.N.
• Email: aholland@nei.nih.gov
• Phone: (301) 435-1831

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Autologous Serum Tears with Hyaluronate vs Standard Serum Tears for Moderate-to-Severe Dry Eye

  This study tests whether adding sodium hyaluronate to autologous serum eye drops provides better relief for adults with moderate-to-severe dry eye in one eye, compared with the standard serum drops in the other eye.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07413172

• Two approaches to repeat eyelid surgery for post-operative trichiasis

  This project will try whether the newer Bevel-Rotate Advancement Procedure (B-RAP) or the standard Bilamellar Tarsal Rotation (BLTR) gives better results for people in Tanzania who need repeat surgery for post-operative trachomatous trichiasis.

  Recruiting at 2 sites University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07322302

• How TRYPTYR affects quality of life and the ability to work for people with dry eye

  This one-month test will see if TRYPTYR (acoltremon) eye drops help adults with chronic dry eye produce more tears, reduce symptoms, and improve their ability to do work.

  Recruiting at 3 sites Phase 4 Southern College of Optometry · Pittsburg, Kansas and 2 other locations · NCT07266948

• Course of EYS-associated retinitis pigmentosa in adults from Russia and former CIS

  We will follow adults with pathogenic EYS gene variants from Russia and former CIS for four years to try to find reliable vision and retinal measures for future treatments.

  Recruiting Sensor Technology for Deafblind · Moscow · NCT07228793

• Dapagliflozin (an SGLT2 inhibitor) for slowing geographic atrophy in dry AMD

  This trial will test whether taking dapagliflozin once daily can slow the growth of geographic atrophy in people aged 50 and older with dry age-related macular degeneration.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07174687

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.